The German ADPKD Tolvaptan Treatment Registry is a Prospective, Observational, Multicentric Study of Patients Suffering From ADPKD That Are Considered for Tolvaptan Treatment.
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 2,000
- 试验地点
- 12
- 主要终点
- Drug dosing and titration as a measure of changes in real-life setting
研究概览
简要总结
The German ADPKD Tolvaptan Treatment Registry is a prospective, observational, multicentric study of patients suffering from ADPKD that are considered for tolvaptan treatment. All ADPKD patients that are evaluated for treatment indication, or that are planned to be treated with tolvaptan, or that are already treated with tolvaptan are eligible. This registry is designed to provide "real-world" data on treatment management of patients with ADPKD.
详细描述
A substantial number of ADPKD patients treated in our center or referred to our center for counseling are considered eligible for tolvaptan treatment and, thus, will be invited to enter the registry. Furthermore, many patients with ADPKD are treated by nephrologists in practices. We operate a network with many of these practices and will expand this network. Patients can be enrolled - after having obtained approval by the local ethics committee - at external sites (expected number: about 500 patients per year). We are also closely liaised with the German self-help group PKDCure (PKD Familiaere Zystennieren e.V.), which is dedicated to ADPKD-linked research. Recruitment of patients will be facilitated by intensified interacting with these groups. Usually, patients that are referred to our institution for evaluation or counseling are regularly seen once a year. No additional trial-related visits in our institution will be required which is in line with the observational nature of the trial. However, data recording is not restricted to parameters assessed at our center but does include also parameters assessed by the treating physician.
SOPs (Standard Operating Procedures) that include further diagnostic tests like MRI are applied routinely in ADPKD patient management in our institution. The data obtained from these tests will be entered in the registry.
At enrolment, clinical, laboratory data and imaging study findings are collected after obtaining informed consent. The parameters listed below constitute the core data set, additional parameters can be included if considered essential.
Clinical data:
- demographic data (sex, age, height, weight)
- family history
- genotype (if available)
- extrarenal ADPKD manifestations
- co-morbidities
- medication
- physical examination
- blood pressure
- no. of extrarenal and renal complications in the past 12 months (urinary tract infections, pain episodes, macrohematuria, kidney stones, hospital admissions, ...)
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years
- •ADPKD proven by positive family history and evidence of renal cysts or diagnosed by treating physician
- •Presentation at our center for tolvaptan treatment indication, or tolvaptan treatment planned, or tolvaptan already started
排除标准
- •Patients not capable of giving informed consent
- •End stage renal disease requiring renal replacement therapy
- •Patients receiving tolvaptan as "off-label use"
结局指标
主要结局
Drug dosing and titration as a measure of changes in real-life setting
时间窗: 10 years
Drug dosing and titration as a measure of maximum dose and the final dose and how fast it is achieved
Urine osmolarity as a measure of appropriate dosing
时间窗: 10 years
Data on urine osmolarity will be collected to measure appropriate dosing to provide the desired protective effect
Evaluation of rate of drug discontinuation and average Duration of therapy
时间窗: 10 years
Evaluation of rate of drug discontinuation and average Duration of therapy
次要结局
- Liver enzymes(10 years)
- Clinical and biochemical characteristics during follow-up(10 years)
- Clinical and biochemical characteristics at enrolment and treatment initiation(10 years)
- Evolution of TKV(10 years)
- Demographics(10 years)
- Side effects(10 years)
- Evolution of estimated glomerular Filtration rate (eGFR) over the Observation period(10 years)
- Urinary output(10 years)
研究者
Roman Müller
MD, Prof.
University Hospital of Cologne
